montelukast and Drug-Overdose

Limited information exists on the toxicity of pediatric ingestions of the drug montelukast used in the treatment of chronic asthma. All ingestions of montelukast involving children age 0-5 yr reported to Texas poison control centers during 2000-2005 were retrieved. For a subset of cases where the final medical outcome and dose in milligrams or milligrams per kilogram were known, the pattern of exposures by final medical outcome and management site was evaluated. There was a total of 3698 cases. Of those cases with a known final medical outcome and dose, the mean dose in milligrams was 42.5 mg (range 0.4-536 mg) and the mean dose in milligrams per kilogram was 3.36 mg/kg (range 0.18-33.71 mg/kg). The final medical outcome was no observed effect in 95% of the cases and minor effect in the remainder of the cases. The patient was managed on site in 80% of the cases. The proportion of cases with a minor effect increased from 5% for ingested dose of < or = 100 mg to 10% for > 100 mg but was 5% for dose < or = 5 mg/kg and > 5 mg/kg. The proportion of cases managed with health care facility involvement increased from 15% for ingested dose of < or = 100 mg to 56% for > 100 mg and rose from 10% for dose < or = 5 mg/kg to 47% for dose > 5 mg/kg. Pediatric montelukast ingestions of doses up to 536 mg or 33.71 mg/kg do not appear likely to result in serious adverse effects and usually can be managed at home.

Topics: Acetates; Administration, Oral; Anti-Asthmatic Agents; Child, Preschool; Cyclopropanes; Dose-Response Relationship, Drug; Drug Overdose; Female; Humans; Infant; Male; Poison Control Centers; Quinolines; Retrospective Studies; Sulfides; Texas

Topics: Acetates; Anti-Asthmatic Agents; Cyclopropanes; Drug Overdose; Emergency Medical Services; Female; Humans; Infant; Leukotriene Antagonists; Quinolines; Sulfides

Topics: Acetates; Anti-Asthmatic Agents; Asthma; Child, Preschool; Cyclopropanes; Drug Overdose; Humans; Leukotriene Antagonists; Male; Quinolines; Sulfides; Treatment Outcome